Get started
Author

Pakeeza Zahra Sayyed

The delivery of antisense therapeutics
2000 · Saghir Akhtar, Marcus D. Hughes, et al. · Advanced Drug Delivery Reviews · 215
Sustained Polymeric Delivery of Gene Silencing Antisense ODNs, siRNA, DNAzymes and Ribozymes:In VitroandIn VivoStudies
2004 · Alim Khan, Mustapha Benboubetra, et al. · Journal of drug targeting · 134
Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
2014 · Antonio Salar, Irit Avivi, et al. · Journal of Clinical Oncology · 98
The cellular delivery of antisense oligonucleotides and ribozymes
2001 · Marcus D Hughes, Majad Hussain, et al. · Drug Discovery Today · 94
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial
2016 · Sarit Assouline, Valeria Buccheri, et al. · The Lancet Haematology · 45
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
2015 · Sarit Assouline, Valeria Buccheri, et al. · British Journal of Clinical Pharmacology · 41
PDF
MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types
2018 · I. Chau, G.M. Haag, et al. · Annals of Oncology · 19
A Two-Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Rituximab In Patients with Follicular Lymphoma as Part of Maintenance Treatment
2010 · Antonio Salar, Reda Bouabdallah, et al. · Blood · 12
MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.
2018 · Do-Youn Oh, Salah-Eddin Al-Batran, et al. · Journal of Clinical Oncology · 10
Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL)
2012 · Antonio Salar, Irit Avivi, et al. · Blood · 8
1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
2020 · E. Felip, F.L. Lim, et al. · Annals of Oncology · 7
Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab
2012 · Sarit Assouline, Valeria Buccheri, et al. · Blood · 6
Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)
2020 · Byoung Chul Cho, Nathan Bahary, et al. · Cancer Research · 4
Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.
2021 · Jayesh Desai, Marwan Fakih, et al. · Journal of Clinical Oncology · 3
1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer
2021 · J. Lee, J.A. Ajani, et al. · Annals of Oncology · 2
Practical experience with rituximab subcutaneous
2015 · Sarah Liptrott, Nicola Crosbie, et al. · Cancer Nursing Practice · 1
Clinical Development of Novel-Novel Multi-Company Combination Therapies in Oncology
2026 · Patrick Y. Muller, Johannes Eisinger, et al. · Current Oncology Reports
Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)
2014 · Sarit Assouline, Valeria Buccheri, et al. · Blood
Evaluation of DNA enzymes targeted against the RNA component of human telomerase
2002 · Sayyed, Pakeeza Z. · Aston Publications Explorer (Aston University)
PDF
Works count: 19
Citation count: 699
H-index: 9
I10-index: 9
Year
Topic
Type